

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Liver graft preconditioning, preservation and reconditioning

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1609114> since 2016-11-10T23:24:53Z

Published version:

DOI:10.1016/j.dld.2016.06.031

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Accepted Manuscript

Title: Liver graft preconditioning, preservation and reconditioning

Author: Nicholas Gilbo Giorgia Catalano Mauro Salizzoni
Renato Romagnoli



PII: S1590-8658(16)30506-0
DOI: <http://dx.doi.org/doi:10.1016/j.dld.2016.06.031>
Reference: YDL D 3196

To appear in: *Digestive and Liver Disease*

Received date: 18-1-2016
Revised date: 2-5-2016
Accepted date: 27-6-2016

Please cite this article as: Gilbo N, Catalano G, Salizzoni M, Romagnoli R, Liver graft preconditioning, preservation and reconditioning, *Digestive and Liver Disease* (2016), <http://dx.doi.org/10.1016/j.dld.2016.06.031>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Liver graft preconditioning, preservation and reconditioning

Nicholas Gilbo, MD, Giorgia Catalano, MD, Mauro Salizzoni, MD, Renato Romagnoli, MD.

Liver Transplantation Center, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy

Correspondence to:

Prof. Dr. Renato Romagnoli, MD, FEBS

Liver Transplantation Center and General Surgery Unit 2U

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

University of Turin, C.so Bramante 88, 10126, Torino, Italy

E-mail: renato.romagnoli@unito.it

Telephone: +39 011 6334374

Fax: +39 011 6336770

Financial Disclosure: the authors of the manuscript have nothing to disclose

Word Count: 5,000 words

Abstract

Liver transplantation is the successful treatment of end-stage liver disease; however, the ischemia-reperfusion injury still jeopardizes early and long-term post-transplant outcomes. In fact, ischemia-reperfusion is associated with increased morbidity and graft dysfunction, especially when suboptimal donors are utilized. Strategies to reduce the severity of ischemia-reperfusion can be applied at different steps of the transplantation process: organ procurement, preservation phase or before revascularization. During the donor procedure, preconditioning consists of pre-treating the graft prior to a sustained ischemia either by a transient period of ischemia-reperfusion or administration of anti-ischemic medication, although a multi-pharmacological approach seems more promising. Different preservation solutions were developed to maintain graft viability during static cold storage, achieving substantial results in terms of liver function and survival in good quality organs but not in suboptimal ones. Indeed, preservation solutions do not prevent dysfunction of poor quality organs and are burdened with inadequate preservation of the biliary epithelium. Advantages derived from either hypo- or normothermic machine perfusion are currently investigated in experimental and clinical settings, suggesting a reconditioning effect possibly improving hepatocyte and biliary preservation and resuscitating graft function prior to transplantation. In this review, we highlight acquired knowledge and recent advances in liver graft preconditioning, preservation and reconditioning.

Key words: liver transplantation, preservation, preconditioning, reconditioning

Introduction

Liver transplantation (LT) is the ultimate treatment for end-stage liver disease, achieving substantial early and long-term results. However, the Ischemia-Reperfusion Injury (IRI) profoundly influences outcomes after LT, representing still a considerable challenge.

The success of LT has created a new dilemma: the organ supply does not satisfy a steadily increasing demand; to overcome this limit, the criteria for organ donation have become less restrictive by including grafts of suboptimal quality, such as those from Extended Criteria Donors (ECD) (i.e. mainly those with significant macrosteatosis, old donor age or prolonged hospitalization) or Donation after Circulatory Death (DCD)⁽¹⁾. Unfortunately, suboptimal grafts are more susceptible to IRI and carry an increased risk of organ failure after transplantation⁽²⁾. It is now clear that IRI represents a major hurdle we must deal with to further improve LT outcomes, thus satisfying patients' needs.

Living donation, minimizing the duration of cold ischemia, may represent a solution to both IRI and shortage of donor grafts. The large experience accumulated by the Asian groups showed indeed that living donation can satisfactorily replace a limited pool of deceased donors, achieving excellent survival^(3,4). However Western experience is still far from reaching comparable numbers in terms of both LT performed and patient survival, and considerable concerns regarding donor safety and post-transplant graft failure still exist. Hence, researchers have consistently focused on reducing the severity of IRI with interventions that can be applied at different steps of deceased donor LT (Figure 1).

The phase of procurement at the donor site offers the opportunity to treat the graft prior to the initiation of IRI, a concept known as organ *preconditioning*.

Maintaining the viability of the graft during the cold storage phase with dedicated solutions is probably the oldest attempt to reduce IRI, but the renewed interest in machine perfusion (MP) pushes towards new appealing scenarios in organ *preservation*.

Recent advances in experimental MP have prompted the possibility to assess graft viability and to resuscitate it immediately prior to LT, performing a real organ *reconditioning*.

Here, we review the acquired knowledge and highlight the emerging evidences on the effects of graft preconditioning, preservation and reconditioning in LT.

1. Ischemia-Reperfusion Injury: pathogenesis and clinical implications

IRI inevitably occurs through the transplantation process from organ donation to graft revascularization. During the procurement, the graft is suddenly deprived of oxygen and cooled down with cold preservation solutions in order to slow metabolic processes. Yet, at 4°C metabolism is not fully stopped, ATP is progressively depleted and mitochondrial function dysregulated. After reperfusion, the production of reactive oxygen species, cytokines secretion, neutrophil infiltration and the impaired hepatic microcirculation provoke inflammation, cell death, loss of functioning parenchyma and ultimately organ failure^(5,6). Additionally, cholangiocytes are more susceptible to IRI and extended damage of the biliary epithelium is visible at the end of preservation of virtually all grafts^(7,8). Peribiliary vascular plexus and glands (containing the precursor's niche) are also damaged by microthrombi and necrosis, leading to impaired regeneration of the biliary epithelium. The physiological systems buffering the detergent effect of bile salts are dysregulated during the preservation phase, hence a toxic damage superimpose to the injuries of the biliary tree⁽⁹⁾. All these mechanisms are responsible of the development of Non Anastomotic biliary Strictures (NAS), a troublesome complication characterized by multiple stenosis of the bile ducts. Histological features of IRI include hepatocytes swelling, apoptosis, necrosis, sinusoidal endothelial cells detachment and polymorphonucleate infiltration⁽¹⁰⁾.

The clinical manifestation of IRI can vary from immediate graft function with minimal damage to Early Allograft Dysfunction (EAD), Primary Non Function (PNF) and NAS. EAD is the result of the hepatocellular necrosis and it is biochemically evident as highly elevated transaminases and/or impaired synthetic function (elevated total bilirubin, prolonged coagulation) within the 1st week post-LT⁽¹¹⁾. PNF is a life threatening condition in which the liver graft immediately fails on sustaining the physiological metabolic demands but a uniformly accepted definition is currently missing. Both graft and patient survival are severely reduced by the occurrence of EAD or PNF. NAS also represents a common cause of graft loss especially after transplantation of DCD grafts⁽¹²⁾.

Strategies preventing IRI should reduce the incidence of its manifestations; clinical studies evaluating the efficacy of such strategies should therefore focus on transaminases peak post-LT, incidence of EAD/PNF, incidence of NAS and graft survival.

2. Preconditioning (see Table 1)

Organ procurement offers a window for pre-treating the liver with several strategies. The most commonly attempted ones, are the Ischemic Preconditioning (IP) and the pharmacological preconditioning, i.e. administering medications effective against IRI.

2.1. Ischemic preconditioning

After the first report on the protective effect of transient run of IRI in the myocardium by Murray *et al.*⁽¹³⁾, IP effect was evaluated and confirmed in different organs such as kidney and liver. The underlying protective mechanisms seem related to the increased production of protective mediators, antioxidants and inhibitor of apoptosis prior to the onset of IRI⁽¹⁴⁾.

Different clinical trials have evaluated the effectiveness of IP applying different duration of ischemia and reperfusion. Koneru *et al.* first performed IP using a protocol consisting of five minutes of ischemia and five minutes of reperfusion before the beginning of cold ischemia. In a randomized trial involving 60 LTs no differences were found in surrogate or pathological markers of IRI⁽¹⁵⁾. Azoulay *et al.* used a protocol of ten minutes ischemia - ten minutes reperfusion and demonstrated a significant reduction of post-LT transaminase release. Despite this protective effect, IP significantly increased the incidence of EAD, although no impact on patient and graft survival was observed⁽¹⁶⁾. In our previous experience comparing the effect of IP (ten minutes ischemia – thirty minutes reperfusion) in both optimal and ECD grafts, post-transplant transaminases release was significantly reduced, especially in ECD grafts treated by IP, and the severity of histological IRI was improved. However, no difference was observed in functional recovery or incidence of EAD, although a trend towards better graft and patient survival was observed in a short-term follow-up (6 months). We concluded that, even if IP in suboptimal grafts showed a protective effect, it was not able to prevent the functional impairment often observed after LT with ECD grafts⁽¹⁷⁾. Degli Esposti *et al.* partly confirmed our findings analyzing steatotic and non-steatotic grafts undergoing IP. Steatotic grafts displayed reduction of necrosis and enhancement of autophagy after IP while no significant impact in non-steatotic grafts was observed⁽¹⁸⁾. Finally, a recent meta-analysis detected no improvement in post-transplant transaminases release, no differences in PNF, mortality, or retransplantation. Authors

concluded that there are no evidences to support or to refute the use of IP during liver procurement⁽¹⁹⁾.

The utility of IP in the setting of LT is far to be proven since clinical trials showed controversial results and data on the impact on long-term graft survival are still missing. Hence, IP should be used today only in the frame of experimental studies.

2.2. Pharmacological preconditioning

IRI has a complex pathogenesis where several harmful pathways are at play; inflammation is probably the most evident change and its severity is directly related to ischemia duration. Anti-inflammatory medication might be used to reduce IRI. Kotsch et *al.* tested the effectiveness of donor pulse infusion of methylprednisolone from the declaration of brain death (DBD) until organ procurement. In 100 DBD donors, the systemic concentration of pro-inflammatory cytokines (IL-6, IL-2, TNF- α) and the release of transaminases post-LT was reduced in donors randomly treated with steroids. Furthermore, mRNA quantification in biopsies taken at the beginning of the procurement showed a reduced expression of pro-inflammatory genes (TNF- α , IL-6, adhesion molecules and MHC class II). Untreated grafts more frequently experienced severe biopsy-proven acute rejection whilst no differences in incidence of PNF was observed⁽²⁰⁾. Preconditioning with methylprednisolone in the donor seemed to counterbalance the pro-inflammatory effects of brain death and to effectively reduce the severity of inflammation after graft reperfusion.

Tacrolimus is an immunosuppressant that inhibits the activation of T lymphocytes and subsequently the release of chemokines; thus, tacrolimus exerts anti-inflammatory effects too. In a randomized trial involving 26 LTs, Kristo et *al.* evaluated the efficacy of tacrolimus infusion in the graft through the portal vein (1,500 ml of 5% albumin containing 20 ng/ml tacrolimus). Preconditioning with tacrolimus did not reduce transaminases release; markers of hepatic function (bilirubin, prothrombin time) did not differ between groups, thus tacrolimus preconditioning did not influence functional recovery. However, micro-array analysis showed significant reduction of genes related to inflammation in grafts pretreated with tacrolimus⁽²¹⁾. The effectiveness of tacrolimus preconditioning is therefore still unclear and should be investigated in further studies.

Microcirculatory disturbances are related to direct damage of sinusoidal endothelial cells and platelet aggregation but also to decreased nitric oxide (NO), which is an endogenous vasodilator produced by nitric-oxide-synthase (NOS) whose function is impaired by IRI⁽²²⁾. Restoration of NO content may be achieved with administration of inhaled-NO. In a randomized placebo-controlled trial, Lang *et al.* tested the efficacy of NO inhalation during the operative phase prior to graft reperfusion in 20 LTs. Reduction of transaminases release and functional recovery was significantly faster in recipients pretreated with NO, despite no differences in tissue markers of inflammation were observed⁽²³⁾. Administration of NO during LT seemed therefore to improve functional recovery rather than directly reduce IRI, but survival analysis was not performed in the study.

It was postulated that sevoflurane, a volatile anesthetic that can activate NOS, might reduce IRI. Minou *et al.* randomly assigned 40 consecutive DBD donors to receive sevoflurane during liver procurement and observed a significant reduction of post-LT transaminases release. Furthermore, sevoflurane reduced the incidence of EAD selectively in steatotic grafts⁽²⁴⁾. A recent multicenter randomized clinical trial, however, showed no advantage of sevoflurane anesthesia in LT. More than 100 recipients were assigned to receive inhaled sevoflurane during transplantation. The severity of hepatic injury (post-LT transaminase release) was similar in the study groups and no differences were observed in markers of hepatic function (bilirubin, prothrombin time). In contrast with the previous study, sevoflurane did not reduce the incidence of EAD, but the two protocols differed in timing of sevoflurane preconditioning (donor *vs.* recipient procedure)⁽²⁵⁾. Hepatocyte injury after reperfusion is mediated by the release of reactive oxygen species with subsequent oxidative stress. Glutathione (GSH) is the major endogenous buffer involved in radical-free removal, whose synthesis is limited by the availability of precursors, especially cysteine. N-acetyl-cysteine (NAC) is a synthetic precursor that rapidly converts to cysteine into hepatocytes, therefore refurbishing GSH content. Several experimental and clinical studies evaluated the effectiveness of NAC administration prior to IRI, with contrasting results. In experimental settings, the vast majority of animal studies observed a significant reduction of transaminases release in animals pretreated with NAC⁽²⁶⁾. However, different human trials reported either little protective or no effect of NAC preconditioning⁽²⁷⁻³⁰⁾. It must be observed that most of these trials considered small number of LTs and very few analyzed graft survival. Therefore, robust data on the effectiveness of NAC administration prior to LT are still missing.

Hypoxia-inducible factor 1alpha (HIF-1alpha) is an oxygen sensible transcription factor that binds to its beta-heterodimer during acute hypoxia and promotes the expression of several genes related to metabolism, neo-angiogenesis and above all apoptosis/survival. The stabilization of the dimeric form of HIF-1 was shown to reduce transaminase release after IRI in animal experiments, via a mechanism probably involving iNOS pathway. However RNA transcription is impaired during ischemia and the restoration of blood flow during reperfusion coincides with the oxidation, degradation of the alpha subunit and ultimately destabilization of HIF heterodimers. Therefore the protection offered by HIF-1alpha signaling during IRI may be not good enough and therapeutic approaches have failed to reach the clinic⁽³¹⁾.

IRI is the result of a complex cascade of inter-related events acting almost at the same time: tackling a single pathway administering a single medication might be not enough to effectively reduce IRI. Monbaliu *et al.* developed a multi-pharmacological IRI modulation, whose effectiveness was tested in a porcine DCD-LT model characterized by high PNF rate. Liver grafts were exposed to 45 minutes of warm ischemia (WI) before cold storage and were randomly treated or not with the pharmacological modulation. Modulated grafts were flushed with streptokinase (fibrinolytic agent) and epoprostenol (vasodilator) at the time of procurement; before, during and immediately after reperfusion of the liver, glycine (Kupffer's cell stabilizer), alpha1-acid-glycoprotein (anti-inflammatory), MAP-Kinase-inhibitor (pro-inflammatory cytokine generation inhibitor), alpha-tocopherol and glutathione (anti-oxidants), and apotransferrin (iron chelator) were administrated intravenously to the recipient animal. Transaminase release tended to be lower and oxidative stress, TNF- α concentration and bile salt-to-phospholipid ratio were significantly reduced in grafts treated with the modulation protocol. Notably, this multifactorial approach completely eliminated PNF, whose incidence was 55% in untreated animals. The multi-pharmacological modulation seems to be more effective compared to single-medication approaches, as it achieved the remarkable goal of preventing organ failure after transplantation⁽³²⁾. If this effect will be confirmed in clinical settings, graft procured from high-risk donors could be transplanted in a safer manner.

3. Preservation (see Table 2)

Static cold storage (SCS) is currently the standard for organ preservation but hypothermia alone does not ensure adequate graft viability. Preservation solutions are required to preserve homeostasis, supporting liver metabolism and delaying cell damage^(33,34). Several solutions are currently available: University of Wisconsin (UW), Histidine-Tryptophan-Ketoglutarate (HTK), Celsior (CS) and the most recent Institute Georges Lopez-1 (IGL-1). They all differ in terms of composition, ion balance, viscosity, osmolality and cost.

UW is a high viscosity colloid solution due to the presence of hydroxyethyl starch (HES), high potassium and low sodium concentration (125 mmol/L and 27 mmol/l, respectively)⁽³⁵⁾. Despite its widespread use, UW carries some side effects: high viscosity might result in impaired flushing with microcirculatory disturbances; high potassium concentration might provoke cardiac arrest in the recipient upon liver reperfusion; finally, ischemic-type biliary lesions are not so rare⁽³⁶⁾.

HTK represents an alternative to UW whose advantages can be summarized in lower viscosity, lower potassium content (10 mmol/l, thus avoiding the risk of hyperkalemia) and better buffering properties⁽³⁴⁾. CS has low viscosity, high sodium and low potassium concentration (100 mmol/l and 15 mmol/l, respectively) and combines the best aspects of both UW and HTK, retaining the buffering properties of HTK (histidine) and the presence of impermeants as in UW (lactobionic acid)^(36,37). Finally, in IGL-1 sodium and potassium concentrations are switched compared to UW ($[Na^+] = 120$ mmol/l, $[K^+] = 25$ mmol/l) and HES is replaced by polyethylene glycol resulting in lower viscosity⁽³⁸⁾. These properties could improve liver wash-out during procurement and reduce IRI^(39,40).

Identifying the best preservation solution is a difficult task, since randomized trials have shown conflicting results; however, some conclusions can be drawn from large series or clustering data from different trials. In a recent meta-analysis, Zuluaga *et al.* reported no differences in LT outcomes when UW was compared to CS or HTK. In particular, no differences were observed in terms of EAD, 1-year patient survival and occurrence of NAS⁽³⁴⁾. Adam *et al.* partly confirmed this observation in their recent retrospective analysis of the European Liver Transplant Registry involving more than 48,000 LTs. Grafts preserved with UW, IGL-1 or CS showed similar 3-year graft survival; however, IGL-1 was associated with better preservation of partial liver grafts as

shown by higher graft survival in this group. Notably, grafts preserved with HTK achieved significantly inferior survival three years post-LT when compared to grafts preserved with other preservation solutions and at multivariate analysis, HTK resulted an independent risk factor for graft loss⁽⁴¹⁾.

HTK was believed equivalent to UW for SCS but less expensive; nevertheless, recent findings highlighted HTK-associated disadvantages. In a large single-center series and a retrospective analysis of UNOS database, the survival of grafts from standard or ECD donors did not differ when grafts were preserved with HTK or UW; however, in subgroup analyses, HTK-preserved grafts achieved significant inferior survival after exposure to long-lasting cold ischemia or procurement from DCD donors^(42,43). Furthermore, two different clinical trials from Meine *et al.* and Gulsen *et al.* reported relevant increases in the incidence of NAS in patients receiving grafts from DCD donors preserved with HTK^(44,45). The reason why HTK is associated with worse outcomes after LT is not fully understood; the lack of antioxidants and oncotic agents might be an explanation. To summarize, the currently available evidence points towards the avoidance of HTK as a preservation solution for livers.

IGL-1 has been previously tested in rat model of isolated liver perfusion and in pig model of auto-transplantation, showing better preservation of cell integrity^(39,40,46). Dondero *et al.*, in a recent randomized trial including fatty livers, failed to demonstrate IGL-1 superiority, proving that it is at least as effective as UW, with less expenses⁽³⁸⁾. However, the outcome of steatotic grafts was not the primary endpoint of this study, which was probably underpowered to draw solid conclusions. Randomized clinical trials comparing IGL-1 to other preservation solutions are still missing, but the recent large-series analysis from Adam *et al.* confirmed good outcomes and postulated possible advantages for IGL-1⁽⁴¹⁾. Further investigation is therefore needed to confirm this hypothesis.

It is important to stress that all the currently available preservation solutions were developed with the purpose to prevent hepatocytes death over the ischemic storage phase. Other cell populations, including cholangiocytes, are probably not so well protected from IRI. Two recent studies focusing on the pathological aspects of the common bile duct, have indeed revealed that the bile duct epithelium is seriously injured at the end of SCS in up to 88% of cases^(7,8). These findings indicate that the bile duct of almost all grafts suffers relevant injury, which might be responsible

for NAS development. These complications add relevant morbidity and significantly reduce long-term graft survival, representing a rising concern due to the increased transplantation of DCD grafts, burdened with markedly higher rates of biliary complications^(47,48). Improved bile duct preservation might be offered by MP, which has been associated with better preservation of the bile duct in experimental settings^(49,50).

4. Reconditioning (see Table 3)

The concept of preserving organs by MP dates back to the 70's⁽⁵¹⁾; however, the simplicity and the increasing success of SCS limited its application until the last decade. These devices consist in closed circuits in which dedicated solutions are pumped into the liver through its vasculature (portal vein, inferior vena cava and hepatic artery), providing oxygen and nutrients. Heat-exchangers connected to the circuit refrigerate or rewarm the perfusate, and different types of perfusion can be performed: hypothermic, normothermic and sub-normothermic.

In order to improve early aerobic metabolism and function, addition of oxygen during SCS was attempted and proven effective in a pilot study in DCD-LT by Treckmann *et al.* in which humidified oxygen was persufflated in the graft via the hepatic veins⁽⁵²⁾. This concept was subsequently confirmed and improved by both *oxygenated* hypothermic and normothermic machine preservation.

In principle, MP better supports graft metabolism by a continuous provision of nutrients and a wash-out effect of catabolites, thus avoiding ATP-depletion^(53,54). Biomarkers released in the perfusate might therefore reflect the functionality of the graft, the measurement of which might help clinicians to assess graft viability and decide whether transplant or discard the liver. Early preclinical studies have shown that the outcome of suboptimal grafts can be reconditioned to the better through a period of MP⁽⁵⁵⁾ thanks to the restoration of the ATP-balance, which would allow the energy-depleted cells to better cope with the metabolic stress upon reperfusion⁽⁵⁶⁾.

4.1. Hypothermic Machine Perfusion

Hypothermic Machine Perfusion (HMP) was the first reaching the clinic fostered by the great success with the kidney experience^(57,58). The group of Guarrera *et al.* was the first to successfully apply HMP throughout the preservation period in humans. In their matched-

controlled series, they demonstrated the feasibility and some advantages of HMP over SCS: less severe IRI and reduction of the release of pro-inflammatory chemokines. However, they did not show improvements in major outcomes, such as EAD or survival^(59,60). In addition, this study presents some limitations, included the utilization of mostly good quality grafts which historically perform well after SCS. It is therefore not surprising that HMP-preserved good quality grafts displayed good function after LT. In a subsequent analysis, the same group preserved 31 ECD livers with HMP and no advantage was observed in this type of grafts: the rate of EAD was not reduced and 1-year patient survival was comparable, despite *post-hoc* analysis showed significant less NAS in HMP grafts⁽⁶¹⁾. Given these limited clinical applications, it is difficult to claim that HMP offers advantages over SCS, especially in suboptimal grafts. Large-size multicenter randomized clinical trials are therefore needed to acquire more evidences. The research team from Zurich has been applying oxygenated hypothermic MP at the end of cold storage (so called HOPE) to recondition liver grafts after DCD donation^(62,63). In porcine DCD grafts, significant reduction of hepatocyte necrosis and transaminase release, recovery of ATP content and increased bile production was observed in recipients of HOPE-treated livers. With a survival analysis, authors showed that HOPE converted PNF into EAD, thus not fully recovering DCD grafts⁽⁶²⁾. Nevertheless, in their clinical human experiences they observed a significant reduction of transaminase release, EAD and NAS in DCD grafts treated with end-ischemic HOPE compared to either DCD or DBD grafts conventionally preserved^(63,64). However, HOPE-treated grafts were exposed to significantly shorter cold ischemia (3 vs. 6.5 hours), which is a well-known risk factor for graft loss and biliary complications in DCD-LT^(48,65). Additionally, the non-randomized multi-center design of their studies is a limitation; further results from large randomized trials are therefore needed to clarify the effect of HOPE.

Preliminary data suggested that HMP better preserves the biliary tree. In a rat model of LT with DCD grafts, Schlegel *et al.* showed that 1-hour HOPE was associated with significant reduction of intrahepatic fibrosis and cholangiocyte proliferation⁽⁶⁶⁾, although bile composition (reflecting cholangiocyte function) was not evaluated. Op den Dries *et al.* showed that HMP, applied as alternative to SCS, successfully prevents arteriolonecrosis of the peri-biliary plexus in pig DCD livers, thus ensuring better perfusion of the biliary tree. Yet, HMP failed to reduce injury to cholangiocyte function as showed by the analysis of the composition of bile produced during isolated reperfusion with autologous blood⁽⁴⁹⁾. Authors claimed that the improvement of arterial

perfusion would favor the recovery of post-ischemic bile ducts, and that this feature could not be observed during the short period of isolated reperfusion adopted in the study (2 hours). However, hypothermia reduces cell metabolism and pumping cold solution does not change this effect: HMP does not seem to couple better preservation with gain of function, despite the re-balanced energetic status. So, HMP applicability in LT remains unclear and large-size randomized clinical trials are required to further elucidate the potential of this new preservation technique.

4.2. Normothermic Machine Perfusion

With normothermic machine perfusion (NMP) the grafts is preserved in a functioning state, providing nutrients and adequate oxygen supply by means of blood-based preservation solutions. The concept of NMP is more appealing since it can completely avoid IRI if applied throughout the preservation phase. Furthermore, NMP allows extensive evaluation of the viability of grafts, opening the door to unique opportunities of intervention to be performed prior to LT.

Schön *et al.* were the first to experiment NMP in a pig model of transplantation⁽⁶⁷⁾, but the vast majority of the knowledge related to NMP comes from further studies of the Oxford group⁽⁶⁸⁾. In a model of pig LT, Brockmann *et al.* compared the effectiveness of NMP and SCS on preserving both heart-beating and DCD grafts exposed to WI for 40 or 60 minutes. Post-LT transaminase release and severity of histological IRI were reduced in both types of grafts preserved with NMP, although the protective effect was less evident in DCD grafts exposed to 60 minutes WI, all of which experienced liver failure over time. Nevertheless, survival of DCD grafts exposed to 40 minutes WI and preserved with NMP was equal to that of heart-beating grafts preserved with the same technique. These results indicated the possibility to convert the outcome of high-risk livers (DCD) to that of 'standard' organs (heart-beating), although this result was observed with prolonged NMP⁽⁶⁹⁾. Indeed, only 20 hours of preservation allowed a significant improvement of animal survival, showing that the protective effect of NMP might not be immediate but time-dependent. Interestingly, grafts developing functional failure after LT showed different behavior already during NMP preservation: some parameters such as transaminase release, bile production and vascular resistance could be used to predict post-transplant viability prior to LT.

Unfortunately, the addition of a short period of cold preservation in DCD grafts resulted detrimental in further experiments from the same group, since the subsequent application of

NMP failed in protecting them from IRI. It must be noted, however, that in this setting all grafts were exposed to 60 minutes WI, in which NMP seems less effective⁽⁷⁰⁾. A phase I human trial applying NMP during the preservation phase confirmed its safety and feasibility⁽⁷¹⁾; furthermore, the enrollment of a multi-center randomized clinical trial comparing NMP and SCS was completed and results are awaited.

Metabolic reconditioning reducing the fat content of steatotic grafts is another appealing characteristic of NMP. Jamieson *et al.* showed that fatty livers undergoing NMP progressively reduced steatosis over time and displayed nearly normal function⁽⁷²⁾. The reduction of the percentage of steatosis in this model required a long run of MP, but this process can be accelerated by supplementing the perfusate with defatting medications. In fact, Nagrath *et al.* showed in obese rats that the addition of forskolin, hypericin, scoparone and visfatin could rapidly reduce the fat content by 50%⁽⁷³⁾. If this effect would be confirmed in the clinical setting, NMP could increase the number of suboptimal steatotic grafts that could be considered for LT after reconditioning.

Minor *et al.* developed an intermediate approach of end-ischemic (sub)NMP in which the liver is slowly warmed up to 20°C. Controlled oxygenated rewarming (COR) has been tested in both animal and clinical studies and it was proved to better restore the energy balance, reduce the transaminase release and improve hepatic function when compared to SCS or HMP^(74,75). These preliminary studies suggested that smoothly increasing the temperature of the graft during MP may be more effective when compared to the abrupt rewarming observed during both NMP and graft reperfusion *in vivo*. This new concept deserves additional investigation,

Preliminary reports have suggested that NMP might better preserve the bile duct. Liu *et al.* using a porcine DCD model showed that 10 hours of NMP reduces injury to the biliary epithelium, as assessed by lower release of markers of cholangiocyte injury in bile (gamma-glutamyl-transferase and lactate dehydrogenase) and significantly milder lesions of the peri-biliary glands and vascular plexus at histology. Moreover, there were active proliferation of the biliary epithelium after 24 hours of isolated reperfusion and improved bile production compared to SCS preserved grafts⁽⁷⁶⁾. This study suggested that NMP might promote bile duct regeneration after substantial injury, such as the one linked to DCD donation. Unfortunately, the model of isolated

ex-vivo reperfusion adopted in the study could not monitor the development of NAS and these interesting findings still need confirmation in clinical settings.

Compared to HMP, the protection induced by NMP seems more profound since significant reduction of PNF and improvement of post-transplant survival was achieved (at least in animal experiments). These two types of MP differ in a fundamental characteristic: the metabolic state of the liver. Granting full metabolism, NMP may allow to dispose of the injuries experienced during the ischemic phase with a first reperfusion round. Indeed, during NMP the liver is reperfused with a blood-based solution in the absence of alloimmunity interference; this might exhaust the burst of reperfusion-associated injuries and promote a less pro-inflammatory environment, improving function and outcome after transplantation. In fact, Izamis *et al.*, in a metabolic fluxes analysis in rat livers, showed that in the first two hours of NMP, ischemic livers consume less oxygen compared to non-ischemic grafts, with enhanced glycogenolysis and anaerobic glycolysis. After two hours, the oxygen consumption equals and the metabolism aligns to that of fresh livers, remaining stable and self-adjustable thereafter⁽⁷⁷⁾. So, ischemic livers show impaired function during the early phase of NMP but, at later stages, they seem to dispose of the previous damage and to change their metabolism improving their function. This hypothesis would cope with the observation that a long period of NMP is required to observe significant improvement in survival⁽⁶⁹⁾. It might be questioned whether applying NMP for a time longer than 10 hours throughout the preservation phase would mean merely preserving or actually reconditioning the graft after ischemic injury. In this regard, NMP potential is even more enhanced by the possibility to treat grafts with medications, gene delivery or stem cell therapy, with the intent to completely recover damaged livers prior to transplantation^(78,79). It is clear that if this possibility would be confirmed, it will greatly help expanding the scarce resource of transplantable liver grafts.

Conclusions

Performing organ transplantation inevitably leads to IRI, which is a potential threat to the success of the procedure. The complex pathogenesis of IRI permits different approaches to prevent or reduce it. Attempts to precondition the graft before IRI onset can be performed either by induction of a transient period of ischemia-reperfusion or by administration of anti-ischemic

medications. IP did not appear to influence short-term outcomes after transplantation, while the administration of some medications before LT showed promising results, although multi-pharmacological modulation of IRI was even more effective in early animal experiments. Preservation solutions are currently worldwide used for SCS with comparable results, except for HTK solution. In fact, large clinical series and meta-analyses suggest that this preservation solution should be avoided due to an increased risk of graft loss. MP not only represents a valid alternative to SCS, but also allows evaluation of graft viability before transplantation and might recover the injury induced by ischemia. This is a newly re-born area of interest, which needs further exploration before drawing ultimate conclusions. Currently available data seems to point toward a more efficient preservation of grafts with NMP. Furthermore, it offers the unique opportunity to treat the organ with novel therapies, converting high-risk suboptimal grafts into transplantable livers. If reconditioning of risky grafts would successfully translate into clinical practice, it will certainly represent a major progress in transplantation, offering a valuable tool to help rebalancing the impaired equilibrium between donor offer and transplant demand.

References

1. Durand F, Renz JF, Alkofer B, Burra P, Clavien P-A, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc.* 2008 Dec;14(12):1694–707.
2. Briceño J, Marchal T, Padillo J, Solórzano G, Pera C. Influence of marginal donors on liver preservation injury. *Transplantation.* 2002 Aug 27;74(4):522–6.
3. Chen C-L, Kabiling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? *Nat Rev Gastroenterol Hepatol.* 2013 Dec;10(12):746–51.
4. Waki K, Sugawara Y, Mizuta K, Fujita H, Kadowaki T, Kokudo N. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance. *Clin Transpl.* 2011;223–35.
5. Jaeschke H. Mechanisms of reperfusion injury after warm ischemia of the liver. *J Hepatobiliary Pancreat Surg.* 1998;5(4):402–8.
6. Fondevila C, Busuttill RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury--a fresh look. *Exp Mol Pathol.* 2003 Apr;74(2):86–93.
7. Brunner SM, Junger H, Ruemmele P, Schnitzbauer AA, Doenecke A, Kirchner GI, et al. Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. *J Hepatol.* 2013 Jun;58(6):1133–9.
8. Hansen T, Hollemann D, Pitton MB, Heise M, Hoppe-Lotichius M, Schuchmann M, et al. Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation--a morphological clue to ischemic-type biliary lesion? *Virchows Arch Int J Pathol.* 2012 Jul;461(1):41–8.
9. Hessheimer AJ, Cárdenas A, García-Valdecasas JC, Fondevila C. Can we prevent ischemic type biliary lesion in DCD liver transplantation? *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc.* 2016 Apr 15;
10. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. *Am J Physiol Gastrointest Liver Physiol.* 2003 Jan;284(1):G15–26.
11. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc.* 2010 Aug;16(8):943–9.
12. Monbaliu D, Pirenne J, Talbot D. Liver transplantation using Donation after Cardiac Death donors. *J Hepatol.* 2012 Feb;56(2):474–85.
13. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation.* 1986 Nov;74(5):1124–36.

14. Selzner N, Boehnert M, Selzner M. Preconditioning, postconditioning, and remote conditioning in solid organ transplantation: basic mechanisms and translational applications. *Transplant Rev Orlando Fla.* 2012 Apr;26(2):115–24.
15. Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc.* 2005 Feb;11(2):196–202.
16. Azoulay D, Del Gaudio M, Andreani P, Ichai P, Sebag M, Adam R, et al. Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function: the ying and the yang. *Ann Surg.* 2005 Jul;242(1):133–9.
17. Franchello A, Gilbo N, David E, Ricchiuti A, Romagnoli R, Cerutti E, et al. Ischemic preconditioning (IP) of the liver as a safe and protective technique against ischemia/reperfusion injury (IRI). *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2009 Jul;9(7):1629–39.
18. Degli Esposti D, Sebah M, Pham P, Reffas M, Poüs C, Brenner C, et al. Ischemic preconditioning induces autophagy and limits necrosis in human recipients of fatty liver grafts, decreasing the incidence of rejection episodes. *Cell Death Dis.* 2011;2:e111.
19. Gurusamy KS, Kumar Y, Sharma D, Davidson BR. Ischaemic preconditioning for liver transplantation. *Cochrane Database Syst Rev.* 2008;(1):CD006315.
20. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. *Ann Surg.* 2008 Dec;248(6):1042–50.
21. Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Mühlbacher F, et al. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. *Transpl Int Off J Eur Soc Organ Transplant.* 2011 Sep;24(9):912–9.
22. Ben Abdennebi H, Zaouali MA, Alfany-Fernandez I, Tabka D, Roselló-Catafau J. How to protect liver graft with nitric oxide. *World J Gastroenterol WJG.* 2011 Jun 28;17(24):2879–89.
23. Lang JD, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. *J Clin Invest.* 2007 Sep;117(9):2583–91.
24. Minou AF, Dzyadzko AM, Shcherba AE, Rummo OO. The influence of pharmacological preconditioning with sevoflurane on incidence of early allograft dysfunction in liver transplant recipients. *Anesthesiol Res Pract.* 2012;2012:930487.
25. Beck-Schimmer B, Bonvini JM, Schadde E, Dutkowski P, Oberkofler CE, Lesurtel M, et al. Conditioning With Sevoflurane in Liver Transplantation: Results of a Multicenter Randomized Controlled Trial. *Transplantation.* 2015 Mar 12;

26. Jegatheeswaran S, Siriwardena AK. Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery. *HPB*. 2011 Feb;13(2):71–8.
27. Rigueira FM, Hernández JL, Sola I, Cienfuegos JA, Pardo F, Díez-Caballero A, et al. Ischemic damage prevention by N-acetylcysteine treatment of the donor before orthotopic liver transplantation. *Transplant Proc*. 1997 Dec;29(8):3347–9.
28. Thies JC, Teklote J, Clauer U, Töx U, Klar E, Hofmann WJ, et al. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. *Transpl Int Off J Eur Soc Organ Transplant*. 1998;11 Suppl 1:S390–2.
29. Steib A, Freys G, Collin F, Launoy A, Mark G, Boudjema K. Does N-acetylcysteine improve hemodynamics and graft function in liver transplantation? *Liver Transplant Surg Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 1998 Mar;4(2):152–7.
30. Weigand MA, Plachky J, Thies JC, Spies-Martin D, Otto G, Martin E, et al. N-acetylcysteine attenuates the increase in alpha-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. *Transplantation*. 2001 Aug 27;72(4):694–8.
31. Guo Y, Feng L, Zhou Y, Sheng J, Long D, Li S, et al. Systematic review with meta-analysis: HIF-1 α attenuates liver ischemia-reperfusion injury. *Transplant Rev Orlando Fla*. 2015 Jul;29(3):127–34.
32. Monbaliu D, Vekemans K, Hoekstra H, Vaahtera L, Libbrecht L, Derveaux K, et al. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. *Ann Surg*. 2009 Nov;250(5):808–17.
33. García-Gil FA, Serrano MT, Fuentes-Broto L, Arenas J, García JJ, Güemes A, et al. Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study. *World J Surg*. 2011 Jul;35(7):1598–607.
34. Lema Zuluaga GL, Serna Agudelo RE, Zuleta Tobón JJ. Preservation solutions for liver transplantation in adults: celsior versus custodiol: a systematic review and meta-analysis with an indirect comparison of randomized trials. *Transplant Proc*. 2013 Feb;45(1):25–32.
35. Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. *Transplantation*. 1988 Apr;45(4):673–6.
36. Parsons RF, Guarrera JV. Preservation solutions for static cold storage of abdominal allografts: which is best? *Curr Opin Organ Transplant*. 2014 Apr;19(2):100–7.
37. Mühlbacher F, Langer F, Mittermayer C. Preservation solutions for transplantation. *Transplant Proc*. 1999 Aug;31(5):2069–70.
38. Dondéro F, Paugam-Burtz C, Danjou F, Stocco J, Durand F, Belghiti J. A randomized study comparing IGL-1 to the University of Wisconsin preservation solution in liver transplantation. *Ann Transplant Q Pol Transplant Soc*. 2010 Dec;15(4):7–14.

39. Ben Abdennebi H, Steghens J-P, Hadj-Aïssa A, Barbieux A, Ramella-Virieux S, Gharib C, et al. A preservation solution with polyethylene glycol and calcium: a possible multiorgan liquid. *Transpl Int Off J Eur Soc Organ Transplant*. 2002 Jul;15(7):348–54.
40. Ben Abdennebi H, Elrassi Z, Scoazec J-Y, Steghens J-P, Ramella-Virieux S, Boillot O. Evaluation of IGL-1 preservation solution using an orthotopic liver transplantation model. *World J Gastroenterol WJG*. 2006 Sep 7;12(33):5326–30.
41. Adam R, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, et al. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2015 Feb;15(2):395–406.
42. Mangus RS, Fridell JA, Vianna RM, Milgrom MA, Chestovich P, Chihara RK, et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2008 Mar;14(3):365–73.
43. Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2009 Feb;9(2):286–93.
44. Meine MH, Zanotelli ML, Neumann J, Kiss G, de Jesus Grezzana T, Leipnitz I, et al. Randomized clinical assay for hepatic grafts preservation with University of Wisconsin or histidine-tryptophan-ketoglutarate solutions in liver transplantation. *Transplant Proc*. 2006 Aug;38(6):1872–5.
45. Gulsen MT, Girotra M, Cengiz-Seval G, Price J, Singh VK, Segev DL, et al. HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: a single center experience. *Ann Transplant Q Pol Transplant Soc*. 2013;18:69–75.
46. Zaoualí MA, Mosbah IB, Abdennebi HB, Calvo M, Boncompagni E, Boillot O, et al. New insights into fatty liver preservation using Institute Georges Lopez preservation solution. *Transplant Proc*. 2010 Feb;42(1):159–61.
47. Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. *Ann Surg*. 2011 Feb;253(2):259–64.
48. Foley DP, Fernandez LA, Levenson G, Anderson M, Mezrich J, Sollinger HW, et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. *Ann Surg*. 2011 Apr;253(4):817–25.
49. Op den Dries S, Sutton ME, Karimian N, de Boer MT, Wiersema-Buist J, Gouw ASH, et al. Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death. *PLoS One*. 2014;9(2):e88521.

50. Boehnert MU, Yeung JC, Bazerbachi F, Knaak JM, Selzner N, McGilvray ID, et al. Normothermic acellular ex vivo liver perfusion reduces liver and bile duct injury of pig livers retrieved after cardiac death. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2013 Jun;13(6):1441–9.
51. Graham JA, Guarrera JV. “Resuscitation” of marginal liver allografts for transplantation with machine perfusion technology. *J Hepatol*. 2014 Aug;61(2):418–31.
52. Treckmann J, Minor T, Saad S, Ozcelik A, Malagó M, Broelsch CE, et al. Retrograde oxygen persufflation preservation of human livers: a pilot study. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2008 Mar;14(3):358–64.
53. Dutkowski P, Odermatt B, Heinrich T, Schönfeld S, Watzka M, Winkelbach V, et al. Hypothermic oscillating liver perfusion stimulates ATP synthesis prior to transplantation. *J Surg Res*. 1998 Dec;80(2):365–72.
54. Tolboom H, Pouw RE, Izamis M-L, Milwid JM, Sharma N, Soto-Gutierrez A, et al. Recovery of warm ischemic rat liver grafts by normothermic extracorporeal perfusion. *Transplantation*. 2009 Jan 27;87(2):170–7.
55. Fuller BJ, Busza AL, Proctor E. Possible resuscitation of liver function by hypothermic reperfusion in vitro after prolonged (24-hour) cold preservation--a 31P NMR study. *Transplantation*. 1990 Sep;50(3):511–3.
56. Minor T, Paul A. Hypothermic reconditioning in organ transplantation. *Curr Opin Organ Transplant*. 2013 Apr;18(2):161–7.
57. Moers C, Smits JM, Maathuis M-HJ, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. *N Engl J Med*. 2009 Jan 1;360(1):7–19.
58. Jochmans I, Moers C, Smits JM, Leuvenink HGD, Treckmann J, Paul A, et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. *Ann Surg*. 2010 Nov;252(5):756–64.
59. Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2010 Feb;10(2):372–81.
60. Henry SD, Nachber E, Tulipan J, Stone J, Bae C, Reznik L, et al. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2012 Sep;12(9):2477–86.
61. Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al. Hypothermic machine preservation facilitates successful transplantation of “orphan” extended criteria donor livers. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2015 Jan;15(1):161–9.
62. De Rougemont O, Breitenstein S, Leskosek B, Weber A, Graf R, Clavien P-A, et al. One hour hypothermic oxygenated perfusion (HOPE) protects nonviable liver allografts donated after cardiac death. *Ann Surg*. 2009 Nov;250(5):674–83.

63. Dutkowski P, Schlegel A, de Oliveira M, Müllhaupt B, Neff F, Clavien P-A. HOPE for human liver grafts obtained from donors after cardiac death. *J Hepatol*. 2014 Apr;60(4):765–72.
64. Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, et al. First Comparison of Hypothermic Oxygenated PERfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis. *Ann Surg*. 2015 Nov;262(5):764–71.
65. Foley DP, Fernandez LA, Levenson G, Chin LT, Krieger N, Cooper JT, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. *Ann Surg*. 2005 Nov;242(5):724–31.
66. Schlegel A, Graf R, Clavien P-A, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation. *J Hepatol*. 2013 Nov;59(5):984–91.
67. Schön MR, Kollmar O, Wolf S, Schrem H, Matthes M, Akkoc N, et al. Liver transplantation after organ preservation with normothermic extracorporeal perfusion. *Ann Surg*. 2001 Jan;233(1):114–23.
68. Butler AJ, Rees MA, Wight DGD, Casey ND, Alexander G, White DJG, et al. Successful extracorporeal porcine liver perfusion for 72 hr. *Transplantation*. 2002 Apr 27;73(8):1212–8.
69. Brockmann J, Reddy S, Coussios C, Pigott D, Guirriero D, Hughes D, et al. Normothermic perfusion: a new paradigm for organ preservation. *Ann Surg*. 2009 Jul;250(1):1–6.
70. Reddy SP, Bhattacharjya S, Maniakin N, Greenwood J, Guerreiro D, Hughes D, et al. Preservation of porcine non-heart-beating donor livers by sequential cold storage and warm perfusion. *Transplantation*. 2004 May 15;77(9):1328–32.
71. Ravikumar R, Jassem W, Mergental H, Heaton N, Mirza D, Perera MTPR, et al. Liver transplantation after ex vivo normothermic machine preservation: a Phase 1 (first-in-man) clinical trial. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2016 Jan 11;
72. Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. *Transplantation*. 2011 Aug 15;92(3):289–95.
73. Nagrath D, Xu H, Tanimura Y, Zuo R, Berthiaume F, Avila M, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. *Metab Eng*. 2009 Sep;11(4-5):274–83.
74. Minor T, Efferz P, Fox M, Wohlschlaeger J, Lüer B. Controlled oxygenated rewarming of cold stored liver grafts by thermally graduated machine perfusion prior to reperfusion. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2013 Jun;13(6):1450–60.
75. Hoyer DP, Mathé Z, Gallinat A, Canbay AC, Treckmann JW, Rauen U, et al. Controlled Oxygenated Rewarming of Cold Stored Livers Prior to Transplantation: First Clinical Application of a New Concept. *Transplantation*. 2016 Jan;100(1):147–52.

76. Liu Q, Nassar A, Farias K, Buccini L, Baldwin W, Mangino M, et al. Sanguineous normothermic machine perfusion improves hemodynamics and biliary epithelial regeneration in donation after cardiac death porcine livers. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2014 Aug;20(8):987–99.
77. Izamis M-L, Tolboom H, Uygun B, Berthiaume F, Yarmush ML, Uygun K. Resuscitation of ischemic donor livers with normothermic machine perfusion: a metabolic flux analysis of treatment in rats. *PloS One*. 2013;8(7):e69758.
78. Vogel T, Brockmann JG, Coussios C, Friend PJ. The role of normothermic extracorporeal perfusion in minimizing ischemia reperfusion injury. *Transplant Rev Orlando Fla*. 2012 Apr;26(2):156–62.
79. Van Raemdonck D, Neyrinck A, Rega F, Devos T, Pirenne J. Machine perfusion in organ transplantation: a tool for ex-vivo graft conditioning with mesenchymal stem cells? *Curr Opin Organ Transplant*. 2013 Feb;18(1):24–33.

FIGURE LEGEND

Figure 1. Possible strategies to tackle Ischemia-Reperfusion Injury throughout the liver transplantation process and proposed outcome measures in the recipient.

COR: Controlled Oxygenated Rewarming; EAD: Early Allograft Dysfunction; HOPE: Hypothermic Oxygenated Perfusion; HTK: Histidine-Tryptophan-Ketoglutarate; IGL-1: Institute George Lopez 1; NAS: Non-Anastomotic biliary Strictures; PNF: Primary Non Function; UW: University of Wisconsin solution

Accepted Manuscript

Liver graft preconditioning, preservation and reconditioning

Nicholas Gilbo, MD, Giorgia Catalano, MD, Mauro Salizzoni, MD, Renato Romagnoli, MD.

Liver Transplantation Center, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy

Correspondence to:

Prof. Dr. Renato Romagnoli, MD, FEBS

Liver Transplantation Center and General Surgery Unit 2U

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

University of Turin, C.so Bramante 88, 10126, Torino, Italy

E-mail: renato.romagnoli@unito.it

Telephone: +39 011 6334374

Fax: +39 0116336770

Conflict of interest: the authors of the manuscript in line with the policy of the journal declare they do not have any conflict of interest to disclose.

Table 1. Summary of clinical and experimental studies considering preconditioning strategies.

	Study	Characteristics	Endpoints	Results
Ischemic				
Preconditioning				
Koneru et al. (2005) ⁽⁷⁾	Randomized clinical trial	62 LT	Safety	IP safe technique
	IP	IP vs. standard procurement	Liver function (post-LT AST, ALT, bilirubin, INR)	Comparable post-LT liver function
	5 min ischemia 5 min reperfusion			
Azoulay et al. (2005) ⁽⁸⁾	Prospective non-randomized clinical trial	91 LT	Primary: incidence of IPF	Increased incidence of IPF
	IP	IP vs. standard procurement	Secondary: post-LT AST, ALT peak	Reduced post-LT AST, ALT peak
	10 min ischemia 10 min reperfusion		Incidence of acute rejection	Reduced incidence of acute rejection
Franchello et al. (2009) ⁽⁹⁾	Randomized clinical trial	75 LT 64% ECD	Primary: post-LT liver injury (AST, ALT), function (INR, bilirubin, bile output)	Reduced liver injury in IRI in ECD Comparable liver function
	IP	IP vs. standard procurement	Histological severity of IRI	Reduced severity of IRI
	10 min ischemia 30 min reperfusion		Secondary: incidence of infection complication	Reduced incidence of infection complications

			6mo graft-survival subgroup analysis in ECD	Trend toward improved survival (confirmed in ECD)
Degli Esposti et al. (2011) ⁽¹⁰⁾	Retrospective analysis of a prospective non-randomized trial	50 LT, 56% ECD (steatosis) IP vs. standard procurement	Primary: post-LT liver injury (AST, ALT) Secondary: incidence of necrosis (histology) acute rejection	Reduced injury in non-steatotic graft Reduced necrosis in steatotic graft Reduced incidence of acute rejection in steatotic graft IP induces autophagy in steatotic graft

Pharmacological

Preconditioning

Kotsch, et al. (2008) ⁽¹²⁾	Randomized clinical trial	100 LT Donor pulse Methylprednisolone infusion methylprednisolone	Post reperfusion release of pro-inflammatory interleukins Incidence of PNF Incidence of acute rejection	Reduced release of pro-inflammatory interleukins (IL2, IL6, TNF-alpha) Comparable incidence of PNF Reduced incidence and severity of acute rejection
Kristo et al. (2011) ⁽¹³⁾	Randomized clinical trial	26 LT Tacrolimus Intraportal tacrolimus infusion (prior LT)	Primary: inflammatory response (genomic analysis) Secondary: post-LT liver injury (AST, ALT) and function (bilirubin,	Reduced expression of genes related to inflammation and immune response Comparable post-LT liver injury and function

			PT)	
Lang et al. (2007) ⁽¹⁵⁾	Randomized clinical trial	20 LT	Primary: post-LT liver injury (ALT, AST), function (PTT, INR)	Decreased post-LT liver injury, faster functional recovery
	Inhaled NO	LT	Secondary: Tissue inflammation marker (histology)	No changes in inflammatory markers, reduced apoptosis
Minou et al. (2012) ⁽¹⁶⁾	Randomized controlled trial	60 LT	Primary: post-LT liver injury (AST, ALT)	Reduced post-LT liver injury
	Sevoflurane	Donor sevoflurane anaesthesia (DBD)	Secondary: incidence of EAD	Reduced incidence of EAD, especially in steatotic graft
Beck-Schimme et al. (2015) ⁽¹⁷⁾	Multicentre randomized clinical trial	98 LT	Primary: post-LT liver injury (AST)	Comparable post-LT liver injury
	Sevoflurane	Recipient sevoflurane anaesthesia	Secondary: incidence of EAD	Comparable incidence of EAD

DBD: donor after brain death; EAD: early allograft dysfunction; ECD: extended criteria donor; IP: ischemic preconditioning; IPF: initial poor function; IRI: ischemia-reperfusion injury; LT: liver transplantation; PNF: primary non-function.

Table 2. Summary of different clinical studies comparing preservation solutions.

	Study	Characteristics	Endpoints	Results
Meine et al. (2006) ⁽³⁵⁾	Randomized clinical study	102 LT HTK vs. UW	Primary: incidence of PDF Secondary: graft survival, incidence of biliary complications	Comparable incidence of PDF Comparable graft survival Higher incidence of biliary complication in HTK HTK 25.8% vs. UW 8.6.% (p<0.05)
Ben Abdennebi et al. (2006) ⁽³¹⁾	Animal experimental study (pig)	Porcine LT model IGL-1 vs. UW	Transaminase peak	Lower release of transaminase in IGL-1
Mangus et al. (2008) ⁽³³⁾	Retrospective clinical study	698 LT 62% ECD HTK vs. UW	primary: 3-mo mortality and graft loss 1-yr graft and patient survival. Secondary: incidence of biliary complications	Comparable 1-yr graft and patient survival, independently from graft type HTK may reduce incidence of biliary complication
Stewart et al. (2009) ⁽³⁴⁾	Retrospective clinical study	18 586 LT UNOS-database HTK vs. UW	Primary: graft survival Sub-analysis considering graft type (DCD vs. DBD) cold ischemia (short vs. long), donor age	HTK independent risk factor for reduced graft survival especially in DCD and prolonged cold ischemia.
Dondéro et al.	Randomized	140 LT	30-day allograft injury and	IGL-1 is as safe as UW

(2010) ⁽²⁹⁾	clinical trial	IGL-1 vs. UW	function (AST, bilirubin, INR) 30-day incidence of HAT, PNF, NAS	
Garcia Gil et al. (2011) ⁽²⁴⁾	Randomized clinical trial	70 LT CS vs. UW	Primary: incidence of post-reperfusion syndrome Secondary: incidence of PNF, PDF	Lower incidence of post-reperfusion syndrome in CS CS 5.9% vs. UW 21.6 % (p<0.05) No PNF, no PDF
Gulsen et al. (2013) ⁽³⁶⁾	Retrospective clinical trial	35 LT from DCD grafts HTK vs. UW	incidence of biliary complication	Increased biliary complication with HTK HTK 76% vs UW 39% (p<0.05)
Lema Zuluaga et al. (2013) ⁽²⁵⁾	Meta-analysis	CS vs. UW HTK vs. UW CS vs. HTK	Primary: incidence of PNF, PDF Secondary: 4mo graft- and patient-survival incidence of ITBL	Comparable incidence of PNF, PDF Comparable graft and patient-survival Comparable incidence of ITBL
Adam et al. (2015) ⁽³²⁾	Retrospective clinical study	42,869 LT ELTR-registry HTK vs. UW CS vs. UW IGL-1 vs. UW	Graft survival	Comparable survival in UW, CS, IGL-1 Reduced survival in HTK HTK independent risk factor for graft loss

CS: Celsior solution; DBD: donation after brain death; DCD: donation after circulatory death; ELTR: European Liver Transplant Registry; HAT: hepatic artery thrombosis; HTK: Histidine-Tryptophan-Ketoglutarate; IGL-1: Institute George Lopez 1; ITBL: ischemia type biliary lesions; LT: liver transplantation; NAS: non-anastomotic biliary strictures; PDF: primary dysfunction; PNF: primary non-function; UNOS: United Network for Organ Sharing; UW: University of Wisconsin.

Table 3. Summary of clinical and experimental studies considering machine perfusion preservation and reconditioning.

	Study	Characteristics	Machine Perfusion	Endpoints	Results
Hypothermic					
Human					
Studies					
Guarrera et al. (2010) ⁽⁵¹⁾	Non-randomized control-match clinical study	40 LT HMP vs. SCS	4-7 h HMP throughout preservation	Primary: incidence of PNF, EAD 1-mo, 1-yr graft and patient survival Secondary: post-LT liver injury (AST, ALT), function (INR) Length of hospital stay	No PNF in either groups, comparable incidence of EAD No differences in graft and patient survival Reduced AST/ALT peak; comparable post-LT function Reduced ICU and hospital stay
Henry et al. (2012) ⁽⁵²⁾	Non-randomized control-match clinical study	40 LT HMP vs. SCS	HMP throughout preservation (4-7h HMP)	Tissue expression of pro-inflammatory cytokines	Attenuated expression and release of pro-inflammatory cytokines
Dutkowski et al. (2014) ⁽⁵⁵⁾	Non-randomized	16 LT	2.4h SCS + 2h HOPE	Post-LT liver injury (AST,	Comparable release of liver enzymes after

	control- match clinical study	HOPE vs. SCS DCD vs. DBD	vs. SCS	ALT), renal function, incidence of reperfusion syndrome	reperfusion, comparable incidence of kidney failure or reperfusion injury No incidence of biliary complications 6-mo or 9- mo post-LT in DCD treated with HOPE
Guarrera et al. (2015) ⁽⁵³⁾	Non- randomized control- match clinical study	61 LT ECD only HMP vs. SCS	HMP throughout preservation (4-7h HMP)	Primary: incidence of PNF, EAD, vascular complication. 1-yr graft and patient survival Secondary: incidence of biliary complication	Comparable incidence of PNF, EAD and vascular complication Comparable graft and patient survival Reduced incidence of biliary complications
Experimental Studies					
De Rougemont et al. (2009) ⁽⁵⁴⁾	Experimental animal study (pig)	Pig model of LT DCD 60min WI HOPE vs. SCS	HMP reconditioning 6h SCS + 1h HOPE vs. 7h SCS	Primary: serum (AST), tissue marker (ATP, glutathione) of liver injury, bile flow Secondary: animal	Reduced necrosis (AST), improved ATP and glutathione recovery, improved bile flow PNF not eliminated but converted to PDF

				survival	
Schlegel et al. (2013) ⁽⁵⁸⁾	Experimental animal study (rats)	Rodent model of LT DCD 30min WI HOPE vs. SCS	HMP reconditioning 4h SCS + 1h HOPE vs. 4h SCS	Primary: post-LT liver injury (AST, ALT), function (INR, factor V) Secondary: biliary injury and fibrosis	Reduced liver injury, improved function post- LT Reduced cholangiocytes proliferation, decreased biliary fibrosis
Op den Dries et al. (2014) ⁽⁴²⁾	Experimental animal study (pig)	Pig model of LT DCD 30min WI HMP vs. SCS	HMP throughout preservation (4h HMP)	Biliary epithelial injury (biliary LDH, γ GT, histology) and function (biliary pH, bicarbonate)	Comparable biliary epithelial injury and function. Reduced necrosis of the peri- biliary vascular plexus

Normothermic

Human

Studies

Ravikumar et al. (2016) ⁽⁶³⁾	Phase I non- randomized match- controlled clinical trial	60 LT NMP vs. SCS DBD and DCD (safety and feasibility)	NMP throughout preservation (3.5-18.5h)	Primary: 30d graft survival Secondary: peak AST/ALT, EAD, 6mo graft survival	Similar 30d graft survival Reduced peak AST, trend toward reduction of EAD incidence in NMP Similar 6mo graft survival
--	--	--	---	--	---

Experimental

Studies


Schön et al. (2001) ⁽⁵⁹⁾	Experimental animal study (pig)	Pig model of LT DCD 60min WI NMP vs. SCS	NMP throughout preservation (4h NMP)	Post-LT liver injury (AST, ALT, histology), function (INR) Incidence of PNF, animal survival	Reduced liver injury, reduced necrosis, improved functional recovery Elimination of PNF, improved animal survival
	Reddy et al. (2004) ⁽⁶²⁾	Experimental animal study (pig)	Pig isolated liver perfusion model DCD 60min WI 24h NMP vs. 4h SCS + 20h NMP	NMP reconditioning V, acid-base homeostasis, glucose metabolism)	Liver injury (AST, ALT, histology) and function (bile production, factor after SCS NMP failed to resuscitate liver after SCS
Brockmann et al. (2009) ⁽⁶¹⁾	Experimental animal study (pig)	Pig model of LT HBD DCD 40min WI DCD 60min WI NMP vs. SCS	NMP throughout preservation (5h NMP; 20h NMP)	Post- LT liver injury (AST, ALT, histology). Survival	Decreased liver injury and improved histology (40min WI – 20h NMP). No PNF, improved survival (40min WI – 20h NMP)
	Nagrath et al. (2009) ⁽⁶⁵⁾	Experimental animal study (rat)	Rodent isolated liver reperfusion model Steatotic liver	NMP reconditioning VLDL), histology assessment of	Perfusate fat content (triglycerides, 50% (3h NMP)

		Defatting cocktail		steatosis	
Jamieson et al. (2011) ⁽⁶⁴⁾	Experimental	Pig isolated liver	NMP throughout	Liver function (bile	Comparable function
	animal study	perfusion model	preservation	production, factor	during isolated liver
	(pig)	Steatotic liver	(48h NMP)	V, acid-base	perfusion,
		vs.		homeostasis), fat	Increased mobilization
		Normal liver		content	of triglycerides,
					reduction of fat vacuoles
Liu et al. (2014) ⁽⁶⁶⁾	Experimental	Pig isolated liver	NMP throughout	Liver injury (AST,	Reduced liver injury,
	animal study	perfusion model	preservation	histology)	improved histology
	(pig)	DCD 60min WI	(10h NMP)	Biliary epithelium	Reduced injury of the
				preservation and	peri-biliary gland and
		NMP vs. SCS		regeneration	plexus, enhanced
				(histology, Ki-67)	regeneration

DCD: donor after circulatory death; EAD: early allograft dysfunction; HBD: heart beating donor; HMP: hypothermic machine perfusion; HOPE: hypothermic oxygenated machine perfusion; LT: liver transplantation; NMP: normothermic machine perfusion; SCS: static cold storage; PNF: primary non-function; VLDL: very-low density lipoprotein; WI: warm ischemia

DONATION**PRECONDITIONING**


Ischemic
Pharmacological

**STORAGE - TRANSPORTATION****PRESERVATION**

UW/HTK/Celsior/IGL-1

RECONDITIONING

Hypothermic Machine Perfusion
Normothermic Machine Perfusion

**END-ISCHEMIC
RECONDITIONING**

HOPE
COR

TRANSPLANTATION**OUTCOME MEASURES**

Transaminases peak
EAD/PNF
NAS
Graft survival

